Shanghai Junshi Biosciences Co., Ltd. announced Dr. Feng Hui ("Dr. Feng") tendered his resignation from the position of chief operations officer and all other positions in the subsidiaries of the Company with effect from 31 August 2023 due to personal reasons. Following his resignation from the aforesaid positions, Dr. Feng has been re-designated as a non-executive director of the Company ("Director") from his previous role as an executive Director (the "Re-designation"). Dr. Feng was appointed as an executive Director in March 2015, and had served as the chief operations officer of TopAlliance Biosciences Inc. since January 2014, the executive director and legal representative of Shanghai Junshi Biotechnology Co., Ltd. since June 2016, and the executive director and general manager of Suzhou Junmeng Biosciences Co., Ltd. since August 2017.

Dr. Feng took part in the invention of certain registered patents and patents in application in relation to JS001, JS002 and JS004 for Group. Dr. Feng's main experience prior to joining Group includes: from 2003 to 2007, he worked at Albert Einstein College of Medicine; from 2007 to 2010, he was a production manager in Human Zyme Inc.; from September 2010 to November 2013, he was a scientist in MedImmune Inc. (a subsidiary of AstraZeneca). Dr. Feng obtained his bachelor's degree in biological sciences and technology from Tsinghua University, PRC in July 1997 and his Ph.D. degree in molecular pharmacology from Albert Einstein College of Medicine, the United States in September 2003.